Effectiveness and Safety of Lenacapavir-Containing Regimens in Highly Experienced HIV-Infected Patients With Multidrug Resistance: Real-world Results From the French Compassionate Use Program

Open Forum Infectious Diseases 2026 Open access

Read full text
Authors: Constance Delaugerre, Sarah Mafi, Arbnor Zenuni, Gilles Peytavin, Karine Amat, Sophie Seang, Claudine Duvivier, David Chirio, Jean‐Paul Viard, Laurent Hocqueloux, Emilie Estrabaud, Jade Ghosn
+4 more Roland Landman, Lambert Assoumou, Charlotte Charpentier, Karine Lacombe
DOI: 10.1093/ofid/ofag353
Cited by: 1
References: 16

Abstract

Abstract Background Lenacapavir (LEN) with an optimized background regimen (OBR) was evaluated in a French cohort of participants with multidrug-resistant human immunodeficiency virus (HIV) via compassionate use. Methods Adults (n = 42) with HIV-1 (PLWH1, n = 33) or HIV-2 (PLWH2, n = 9), receiving at least 1 dose of LEN plus OBR, were prospectively followed between January 2021 and December 2023. The primary endpoint was virological suppression (plasma HIV-1 RNA [VL]

Fields of Study & Subjects

HIV Research and Treatment HIV/AIDS drug development and treatment Virus-based gene therapy research

Publication details

Journal / source
Open Forum Infectious Diseases
Publisher
Oxford University Press (OUP)
Volume
13
Issue
6
Pages
ofag353–ofag353
Publication date
1 June 2026
Language
EN